Dr. Hoffman-Censits on Challenges With Sequencing for Urothelial Carcinoma

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses challenges facing the sequencing of agents for patients with urothelial carcinoma.

It is a challenge to determine which drug a patient should receive next, which is why it is important to have a discussion with the patient, states Hoffman-Censits.

The more researchers understand which type of bladder cancer responds to which treatment, the better selections will be made for each individual patient, explains Hoffman-Censits.

Related Videos
Brian A. Van Tine, MD, PhD
Jason Luke, MD, FACP
Katherine B. Peters, MD, PhD
Yasushi Goto, MD
Prithviraj Bose, MD, associate professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Jun Ma, MD
Hussein A. Tawbi, MD, PhD
Katsumori Asai, MD, PhD
Related Content